AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) Receives NMPA’s Approval for HER2-Positive Metastatic Breast Cancer
Shots:
- The NMPA has approved Enhertu (HER2-directed ADC) in China as a monotx. for adult patients with unresectable or metastatic HER2+ breast cancer who have received one or more prior anti-HER2-based regimens
- The approval was based on the P-III trial (DESTINY-Breast03) results evaluating Enhertu (5.4mg/kg) vs T-DM1 in 524 patients at multiple sites in Asia, EU, North America, Oceania & South America which showed a 72% reduction in risk of disease progression or death. The safety profile was consistent with prior trials with no new safety concerns
- Enhertu (5.4mg/kg) was approved in 40+ countries for unresectable or metastatic HER2+ breast cancer, based on (DESTINY-Breast03) trial results
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
